JUN 19, 2018 9:30 PM PDT

Cancer-Related Cognitive Impairment aka "ChemoBrain" Needs YOU!

WRITTEN BY: Mauri Brueggeman

With so many cancer patients receiving therapies for treatment, there is a late effect being regularly experienced in a wide variety of patients called Cancer-Related Cognitive Impairment (CRCI) or Post Cancer Cognitive Impairment (PCCI).  The American Cancer Society indicates that as of January 2016, there were 15.5 million people with a history of having cancer in the United States.  It is estimated that worldwide, 14.1 million new cases of cancer are diagnosed annually with this number growing every successive year.  CRCI is often referred to as “chemobrain” or “chemofog”.  It’s estimated that nearly 75% of cancer patients may be affected by this issue.  So, of the 15.5 million people in the US with a history of cancer, roughly 11.6 million will likely experience some aspect of it. 

What is it?

CRCI is a state of reduced mental functioning long after cancer treatment has commenced.  Patients have reported bouts of short- and long-term memory loss, difficulty concentrating, confusion, and difficulty finding words to finish sentences, among other symptoms.  Some investigations suggest that the impairment may start during cancer’s progression, rather than being a true result of treatment.  

Does it last long?

Unfortunately, because CRCI is not well understood, it is difficult to predict how long it might last if a patient is experiencing it.  Equally difficult is predicting who will be affected and when.  This condition can begin as early as during treatment or even 5-10 years after treatment has finished.  It has lasting effects on survivors’ quality of life.

Treatment options

Symptoms of CRCI can only be managed by making adjustments to routines to help minimize the effects.  Most recommend writing dates into a calendar and making notes or to-do lists for tasks.  Keeping a journal of symptoms can help pinpoint if there are certain activities or times of the day that are harder like in the evening when one might be more tired and less able to focus.  There is research in the literature suggesting that physical and mental exercises can reduce the “fog” affecting cognitive functioning.  At this time, there is no drug approved to help reduce the impairment or decrease symptoms experienced.   

Future of CRCI

Currently, CRCI is recognized as a condition that cancer patients and cancer survivors face.  In a recent forum article in Trends in Neurosciences, the authors write that they are looking for a neuroscience approach to CRCI.  There is a need for clinical neuropsychologists and neuroscience researchers to collaborate and develop approach models for individuals experiencing this condition.  As detection and recognition of this condition improves, research can hopefully be designed to illuminate the factors at play and provide solutions for affected individuals who have already dealt with so much as cancer patients.  If you are affected by this condition, talk to your provider in order to increase awareness of CRCI.  If you are a researcher or provider, consider how your expertise could contribute to the body of knowledge related to this condition.  Understanding the mechanisms involved and finding potential solutions will have a lasting impact on millions of people now and in future generations.   

Sources: American Cancer Society, Trends in Neuroscience, Supportive and Palliative Care, International Review of Psychiatry, Psycho-Oncology, Journal of the National Cancer Institute,

About the Author
MEd
Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
AUG 21, 2022
Cancer
The Legacy of Lady Mary Wortley Montagu
AUG 21, 2022
The Legacy of Lady Mary Wortley Montagu
Today, August 21, marks the 260th anniversary of the passing of a pioneer in the medical field.  In 1762, Lady Mary ...
SEP 15, 2022
Cancer
Early-Onset Cancers are Rising: Do We Know Why?
SEP 15, 2022
Early-Onset Cancers are Rising: Do We Know Why?
Early-onset cancers, typically defined as those diagnosed in people aged approximately 20 - 50, have continually increas ...
OCT 04, 2022
Cancer
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
OCT 04, 2022
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
In August, President Biden announced his intention to appoint Dr. Monica M. Bertagnolli as the newest director of the Na ...
OCT 24, 2022
Technology
3D Printing Breast Cancer Tumors
OCT 24, 2022
3D Printing Breast Cancer Tumors
Breast cancer is among the most common types of cancer, particularly among women. In fact, other than skin cancers, it i ...
OCT 28, 2022
Cancer
Pancreatic Tumor Growth and Metastasis Inhibited
OCT 28, 2022
Pancreatic Tumor Growth and Metastasis Inhibited
Pancreatic ductal adenocarcinoma (PDAC), a highly aggressive type of pancreatic cancer, has a very poor prognosis due, a ...
NOV 17, 2022
Cancer
Anti-Aging Supplement Linked to Aggressive Breast Cancer
NOV 17, 2022
Anti-Aging Supplement Linked to Aggressive Breast Cancer
Vitamin B3, also known as niacin, is a generic name for a group of biochemical compounds, including nicotinamide ribosid ...
Loading Comments...